PetMedix
Latest round
- Series B
Last raised
- Aug 2021
Total raised
- $50M
Investors
- 5
About PetMedix
Founded in 2017, PetMedix develops biopharmaceuticals specifically for pets. The company has not undergone notable pivots or changes in strategy., with Thomas ??? also serving as the CEO.PetMedix specializes in developing and commercializing biopharmaceuticals for the veterinary market, focusing primarily on providing innovative therapies for companion animals. Their core product offerings include monoclonal antibodies that are designed to treat various diseases in pets, including cancer and autoimmune disorders. These biologics are formulated to enhance animal health and increase the quality of life for pets suffering from complex conditions. The company targets veterinarians and pet owners as its primary customer base, ensuring that the end users—companion animals—receive effective treatments tailored to their specific health needs.PetMedix generates revenue through a combination of direct sales and strategic partnerships with veterinary clinics and animal health distributors. The company engages in B2B transactions, supplying its pharmaceutical products directly to veterinary practices and leveraging relationships with wholesalers to reach a broader market. Revenue is structured around the sales of their flagship products, which are expected to be priced competitively in the biopharmaceutical sector.In September 2023, Zoetis Inc acquired PetMedix Ltd.00 mn, which includes an additional payment of approximately USD 100 mn based on achieving certain milestones. This acquisition enables Zoetis Inc to enhance its research capabilities and accelerate the development of monoclonal antibody therapies for pets. Plans include the design and launch of new products targeting unmet medical needs in the pet population, as well as potential expansion into new geographic markets, with a focus on Europe and North America in the coming years.
Who invested in PetMedix
5 investors across 2 rounds
See all investors in PetMedix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about PetMedix
Who invested in PetMedix?
PetMedix has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PetMedix raised?
PetMedix has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did PetMedix last raise money?
PetMedix's most recent round on record is a Series B, in Aug 2021.
What does PetMedix do?
Founded in 2017, PetMedix develops biopharmaceuticals specifically for pets.
Where is PetMedix headquartered?
PetMedix is headquartered in Cambridge, UK.
Which VCs invest in companies like PetMedix?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at PetMedix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like PetMedix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.